Use of Alpha-Lipoic Acid in Prevention of Contrast-Induced Nephropathy in Diabetic Patients

REFERENCES

• Davidson C, Stacul F, McCullough PA, CIN consensus working panel. Contrast medium use. Am J Cardiol. 2006;98:42K–52K.
   Web of Science ®Google Scholar
• McCullough PA, Adam A, Becker CR, CIN consensus working panel. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol. 2006;98:5K–13K.
   PubMed Web of Science ®Google Scholar
• Briguori C, Airoldi F, Andrea DD, Renal insufficiency following contrast media administration trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation. 2007;115:1211–1217.
   PubMed Web of Science ®Google Scholar
• McCullough P. Outcomes of contrast-induced nephropathy: experience in patients undergoing cardiovascular intervention. Catheter Cardiovasc Interv. 2006;67:335–343.
   PubMed Web of Science ®Google Scholar
• Cronin RE. Contrast-induced nephropathy: pathogenesis and prevention. Pediatr Nephrol. 2010;25:191–204.
   PubMed Web of Science ®Google Scholar
• Pannu N, Wiebe N, Math M, Stat P, Tonelli M. Prophylaxis strategies for contrast-induced nephropathy. J Am Med Assoc. 2006;295:2765–2779.
   PubMed Web of Science ®Google Scholar
• Persson PB, Tepel M. Contrast medium-induced nephropathy: the pathophysiology. Kidney Int. 2006;69:8–10.
   PubMed Web of Science ®Google Scholar
• Goldenberg I, Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ. 2005;172:1461–1471.
   PubMed Web of Science ®Google Scholar
• Lindholt JS. Radiocontrast induced nephropathy. Eur J Vasc Endovasc Surg. 2003;25:296–304.
   PubMed Web of Science ®Google Scholar
• Stacul F, Adam A, Becker CR, CIN consensus working panel. Strategies to reduce the risk of contrast induced nephropathy. Am J Cardiol. 2006;98:59–77.
   PubMed Web of Science ®Google Scholar
• Gruberg L, Mintz GS, Mehran R, The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol. 2000;36:1542–1548.
   PubMed Web of Science ®Google Scholar
• Rihal CS, Textor SC, Grill DE, Incidence and prognostic importance of renal failure after percutaneous coronary intervention. Circulation. 2002;105:2259–2264.
   PubMed Web of Science ®Google Scholar
• Mehran R, Aymong ED, Nikolsky E, A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393–1399.
   PubMed Web of Science ®Google Scholar
• Sketch MH Jr, Whelton A, Schollmayer E, Prostaglandin E1 Study Group. Prevention of contrast media-induced renal dysfunction with prostaglandin E1: a randomized, double-blind, placebo-controlled study. Am J Ther. 2011;8:155–162.
   Google Scholar
• Gare M, Haviv YS, Ben-Yehuda A, The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. J Am Coll Cardiol. 1999;34:1682–1688.
   PubMed Web of Science ®Google Scholar
• Stone GW, McCullough PA, Tumlin JA, CONTRAST investigators. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. J Am Med Assoc. 2003;290:2284–2291.
   PubMed Web of Science ®Google Scholar
• Matejka J, Varvarovsky I, Vojtisek P, Prevention of contrast-induced acute kidney injury by theophylline in elderly patients with chronic kidney disease. Heart Vessels. 2010;25:536–542.
   PubMed Web of Science ®Google Scholar
• Khoury Z, Schlicht JR, Como J, The effect of prophylactic nifedipine on renal function in patients administered contrast media. Pharmacotherapy. 1995;15:59–65.
   PubMed Web of Science ®Google Scholar
• Patel K, King CA, Jovin IS. Angiotensin-converting enzyme inhibitors and their effects on contrast-induced nephropathy after cardiac catheterization or percutaneous coronary intervention. Cardiovasc Revasc Med. 2011;12:90–93.
   PubMedGoogle Scholar
• ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation. 2011;124:1250–1259.
   PubMed Web of Science ®Google Scholar
• Cakatay U. Pro-oxidant actions of α-lipoic acid and dihydrolipoic acid. Med Hypotheses. 2006;66:110–117.
   PubMed Web of Science ®Google Scholar
• Sehirli O, Sener E, Cetinel S, Yuksel M, Gedik M, Sener G. A-lipoic acid protects against renal ischemia-reperfusion injury in rats. Clin Exp Pharmacol Physiol. 2008;35:249–255.
   PubMed Web of Science ®Google Scholar
• Khabbazi T, Mahdavi R, Safa J, Pour-Abdollahi P. Effects of alpha-lipoic acid supplementation on inflammation, oxidative stress, and serum lipid profile levels in patients with end-stage renal disease on hemodialysis. J Ren Nutr. 2012;22:244–250.
   PubMed Web of Science ®Google Scholar
• Briguori C, Visconti G, Rivera NV, Cystatin C and contrast-induced acute kidney injury. Circulation. 2010;121:2117–2122.
   PubMed Web of Science ®Google Scholar
• Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A. NGAL Meta-analysis Investigator Group. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009;54:1012–1024.
   PubMed Web of Science ®Google Scholar
• Malyszko J, Bachorzewska-Gajewska H, Poniatowski B, Urinary and serum biomarkers after cardiac catheterization in diabetic patients with stable angina and without severe chronic kidney disease. Ren Fail. 2009;31:910–919.
   PubMed Web of Science ®Google Scholar
• Singh U, Jialal I. Alpha lipoic acid supplementation and diabetes. Nutr Rev. 2008;66:646–657.
   PubMed Web of Science ®Google Scholar
• McIlduff CE, Rutkove SB. Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy. Ther Clin Risk Manag. 2011;7:377–385.
   PubMed Web of Science ®Google Scholar
• Koga H, Hagiwara S, Kusaka J, New α-lipoic acid derivative, DHL-HisZn, ameliorates renal ischemia-reperfusion injury in rats. J Surg Res. 2012;174:352–358.
   PubMed Web of Science ®Google Scholar
• Jo SH, Kim HS, Lee JH, Evaluation of alpha lipoic acid to prevent contrast induced nepphropathy: A prospective randomised trial. In: Angioplasty Summit Abstracts, E-Poster, Fourteenth Annual Symposium: Angioplasty Summit 2009 TCT Asia Pacific, April 22–29, 2009.
   Google Scholar
• Ling W, Zhaohui N, Ben H, Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography. Nephron Clin Pract. 2008;108:c176–c181.
   PubMed Web of Science ®Google Scholar
• Li W, Li D, Xu T, Zhang Y, Zhu H, Han F. The value of urinary NGAL on the early diagnosis of contrast induced nephropathy in patients undergoing percutaneous coronary intervention. Heart. 2011;97:A150.
   Google Scholar